Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13), Zacks reports.
Alpha Tau Medical Stock Performance
Shares of DRTS stock opened at $2.66 on Thursday. Alpha Tau Medical has a fifty-two week low of $1.75 and a fifty-two week high of $4.39. The stock has a 50 day moving average price of $3.29 and a two-hundred day moving average price of $2.78. The company has a market capitalization of $186.00 million, a P/E ratio of -6.19 and a beta of 0.87.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Alpha Tau Medical in a research report on Friday, November 22nd.
About Alpha Tau Medical
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Read More
- Five stocks we like better than Alpha Tau Medical
- How Can Investors Benefit From After-Hours Trading
- 3 Stocks With Ironclad Balance Sheets for Long-Term Stability
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- How to invest in marijuana stocks in 7 steps
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
